Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)vsEli Lilly and Company (LLY)
LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock
$3.43
-4.60%
HEALTHCARE · Cap: $6.21M
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LABT
Avoid17
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : LABT
The strongest argument for LABT centers on Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : LABT
The primary concerns for LABT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
LABT profiles as a value stock while LLY is a growth play — different risk/reward profiles.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 17/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lakewood-Amedex Biotherapeutics Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Labtec Inc (Ticker: LABT) is a leading biotechnology company focused on pioneering advancements in drug delivery systems and diagnostic solutions. The firm employs innovative technologies and strategic partnerships to tackle significant healthcare challenges, thereby enhancing patient outcomes. With a robust portfolio and a commitment to addressing unmet medical needs, Labtec is strategically positioned for growth in the dynamic biotech landscape, making it an attractive investment opportunity for institutional investors.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?